Skip to main content
ArcticZymes Technologies logo

ArcticZymes Technologies — Investor Relations & Filings

Ticker · AZT ISIN · NO0010014632 LEI · 5967007LIEEXZXGR7K47 BR Manufacturing
Open in API
Filings indexed 973 across all filing types
Latest filing 2017-08-17 Report Publication Anno…
Country NO Norway
Listing BR AZT

About ArcticZymes Technologies

https://arcticzymes.com/

ArcticZymes Technologies is a life sciences company specializing in the development, manufacturing, and commercialization of novel recombinant enzymes. Leveraging over 30 years of expertise, the company discovers and engineers enzymes from cold-adapted Arctic marine organisms. These enzymes are designed to solve specific challenges in molecular applications, demonstrating high efficiency in demanding conditions such as low temperatures and high salinity. The product portfolio, including Salt Active Nucleases (SAN) and Cod Uracil-DNA Glycosylase, serves global partners in molecular diagnostics, gene therapy, vaccine production, and biomanufacturing. All products are manufactured at its ISO 13485 certified facility, ensuring high quality and performance for research and commercial use.

Recent filings

Filing Released Lang Actions
Biotec Pharmacon: Q2 2017 Results and presentation
Report Publication Announcement Classification · 98% confidence The document explicitly states it concerns the 'Q2 2017 Results and presentation' and mentions the 'interim report for the second quarter of 2017'. It also states, 'Please find the Q2 2017 report and presentation attached.' This indicates the document is an announcement about the release of interim financial results and associated presentation materials, rather than the full report itself. Since it announces the release of an interim report (Q2 results), the most appropriate classification is Interim / Quarterly Report (IR). However, given the very short length (1328 chars) and the explicit statement that the report and presentation are 'attached' or available via webcast, it strongly aligns with the 'MENU VS MEAL' rule, suggesting it is a Report Publication Announcement (RPA). Since both the results (IR) and the presentation (IP) are mentioned as being attached, RPA is the best fit for the announcement wrapper.
2017-08-17 English
Extended distribution agreement with Rogg Verbandstoffe in Germany
M&A Activity Classification · 99% confidence The document text describes an extension of a distribution agreement between Biotec Pharmacon's subsidiary and a German distributor (Rogg Verbandstoffe) for the product Woulgan. This is a specific business development announcement concerning commercial operations and market presence, not a mandatory regulatory filing like a 10-K, an earnings release, or a director's dealing report. It does not fit neatly into the primary financial reporting categories (10-K, IR, ER, MRQ). Since it is a specific operational update that doesn't match the other defined categories (like AGM, MANG, CAP, DIV, etc.), the most appropriate classification is the general regulatory/business announcement fallback category, RNS (Regulatory Filings), as it is a material, non-standard announcement. However, upon reviewing the definitions, 'RNS' is defined as 'General regulatory announcements and fallback category for miscellaneous filings that do not neatly fit into other specific categories.' This announcement is a specific business update. If we strictly adhere to the provided definitions, and since it is not a financial report, a management change, a capital event, or a legal update, RNS serves as the best fit for a material, non-standard corporate announcement.
2017-07-18 English
Extended distribution agreement with Rogg Verbandstoffe in Germany
Regulatory Filings Classification · 100% confidence The document announces the extension of a distribution agreement for a product (Woulgan) in Germany between Biotec Pharmacon's subsidiary and Rogg Verbandstoffe. This is a specific business development update concerning commercial operations and market presence, not a mandatory regulatory filing like a 10-K, an earnings release, or a change in management/board. It does not fit the definitions for AGM-R, 10-K, AR, MANG, CT, CAP, DVA, DLST, DIRS, ER, SR, XLSX, FS, CGR, IRAT, IR, IP, LTR, TAR, MRQ, NAV, DIV, PSI, DEF 14A, RPA, SHA, or POS. It is a specific corporate announcement that is best categorized as a general Regulatory Filing (RNS) as it is a material business event announcement that doesn't fit a more specific category, although it is related to commercial activity.
2017-07-18 English
Biotec Pharmacon ASA: Invitation to Q2 2017 presentation and Capital Markets Day
Investor Presentation Classification · 95% confidence The document is an invitation from Biotec Pharmacon ASA announcing a Capital Markets Day (CMD) scheduled for August 17, 2017, which will follow the Q2 presentation. It details the time, location, agenda topics (Woulgan sales, Animal Health, Enzymes, Cancer opportunity), and registration instructions. This content is focused on providing strategic updates and outlook to investors, which aligns closely with the purpose of an Investor Presentation (IP) or a general update event. Since it is an invitation/announcement for an event that will feature presentations on strategy and outlook, 'Investor Presentation' (IP) is the most fitting category, as CMDs are essentially specialized investor presentations. It is not a formal regulatory filing like 10-K or ER, nor is it a transcript (CT) or a simple dividend notice (DIV).
2017-07-06 English
Biotec Pharmacon ASA: Invitation to Q2 2017 presentation and Capital Markets Day
Investor Presentation Classification · 95% confidence The document is an invitation from Biotec Pharmacon ASA to an event combining the Q2 2017 presentation and a Capital Markets Day (CMD). A Capital Markets Day is a strategic update event aimed at investors and analysts, often involving detailed presentations on strategy, outlook, and business segments (Woulgan, Animal Health, Enzymes, Cancer). This content aligns most closely with an Investor Presentation (IP), which typically covers strategy and detailed business updates for investors, even if it's framed as a CMD invitation. It is not a formal regulatory filing like 10-K or IR, nor is it just an earnings release (ER) which is usually just the highlights. Since it details the content of the upcoming presentation/event, IP is the best fit.
2017-07-06 English
Correction - Annual report 2016
Annual Report Classification · 100% confidence The document is explicitly titled 'ANNUAL REPORT 2016' and contains a comprehensive index listing the Board of Directors' report, consolidated financial statements, notes to the financial statements, and an independent auditor's report. It provides a detailed overview of the company's business areas (Biotec BetaGlucans AS and ArcticZymes AS), operational performance, and strategic outlook for the fiscal year 2016. It meets all criteria for a full Annual Report. FY 2016
2017-06-30 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.